MeSH term
Frequency | Condition_Probility | Animals | 94 | 0.0 |
Cricetulus | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Hamsters | 4 | 0.0 |
Hela Cells | 4 | 0.0 |
Humans | 366 | 0.0 |
Proteins/metabolism | 4 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 171 | 0.0 |
Transfection | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 68 | 0.0 |
Adult | 123 | 0.0 |
Aged | 52 | 0.0 |
Comparative Study | 63 | 0.0 |
Dose-Response Relationship, Drug | 19 | 0.0 |
Female | 181 | 0.0 |
Microscopy, Electron, Scanning | 3 | 1.0 |
Middle Aged | 92 | 0.0 |
Disease Progression | 3 | 0.0 |
Hydrogen-Ion Concentration | 6 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Random Allocation | 4 | 0.0 |
Ascorbic Acid/*pharmacology | 2 | 6.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Adolescent | 49 | 0.0 |
Blood Glucose/analysis | 6 | 0.0 |
Double-Blind Method | 7 | 0.0 |
Fasting | 2 | 0.0 |
Kinetics | 19 | 0.0 |
Male | 190 | 0.0 |
Placebos | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Cells, Cultured | 18 | 0.0 |
Rats | 40 | 0.0 |
Body Height | 2 | 1.0 |
Drug Combinations | 3 | 0.0 |
Prospective Studies | 11 | 0.0 |
*Puberty | 2 | 8.0 |
Time Factors | 27 | 0.0 |
Acrylic Resins | 2 | 8.0 |
English Abstract | 24 | 0.0 |
Polymers | 3 | 2.0 |
Immunoglobulin A/analysis | 5 | 3.0 |
Immunoglobulin G/analysis | 8 | 2.0 |
Immunoglobulin M/analysis | 6 | 2.0 |
Immunohistochemistry | 13 | 0.0 |
*Skin Physiology | 3 | 8.0 |
Analysis of Variance | 5 | 0.0 |
Statistics | 2 | 0.0 |
Surface Properties | 2 | 1.0 |
Water/chemistry | 2 | 5.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
Body Weight | 2 | 0.0 |
Child | 48 | 0.0 |
Follow-Up Studies | 8 | 0.0 |
Infant, Newborn | 18 | 0.0 |
Linear Models | 3 | 0.0 |
Binding Sites | 8 | 0.0 |
Glycosylation | 5 | 0.0 |
In Vitro | 9 | 0.0 |
Macromolecular Substances | 6 | 0.0 |
Molecular Weight | 10 | 0.0 |
Secretory Component/chemistry/*metabolism | 2 | 100.0 |
Amino Acid Sequence | 14 | 0.0 |
Base Sequence | 9 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Molecular Sequence Data | 19 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Pedigree | 3 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Injections, Subcutaneous | 25 | 8.0 |
Radioimmunoassay | 12 | 0.0 |
Rats, Inbred Lew | 2 | 0.0 |
Aged, 80 and over | 14 | 0.0 |
Prognosis | 10 | 0.0 |
*Translocation, Genetic | 2 | 0.0 |
Immunoenzyme Techniques | 12 | 0.0 |
Immunoglobulin A, Secretory/metabolism | 5 | 38.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Diagnosis, Differential | 4 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Osmolar Concentration | 3 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Mice | 30 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 17 | 0.0 |
Insulin-Like Growth Factor I/metabolism | 5 | 2.0 |
Sexual Maturation | 2 | 8.0 |
Bone Development/drug effects | 2 | 33.0 |
Blotting, Western | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 9 | 0.0 |
Pregnancy | 16 | 0.0 |
Secretory Component/*analysis | 19 | 86.0 |
Swine | 2 | 0.0 |
Infant | 17 | 0.0 |
Injections, Intramuscular | 4 | 2.0 |
Saliva/*immunology | 3 | 16.0 |
Serotyping | 2 | 0.0 |
*Meiosis | 5 | 15.0 |
Binding, Competitive | 5 | 0.0 |
DNA/genetics | 3 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Protein Binding | 9 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Biological Markers/analysis | 2 | 0.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 2 | 3.0 |
Respiration, Artificial | 2 | 3.0 |
Secretory Component/*biosynthesis | 3 | 100.0 |
Antigens/immunology | 2 | 1.0 |
Biological Markers | 4 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Hematocrit | 4 | 1.0 |
Hemoglobin, Sickle/analysis | 2 | 20.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Immunoglobulin A, Secretory/*metabolism | 4 | 44.0 |
Secretory Component/*metabolism | 9 | 69.0 |
Permeability | 2 | 1.0 |
Dogs | 7 | 0.0 |
Safety | 2 | 1.0 |
Fluorescent Antibody Technique | 16 | 0.0 |
Mice, Inbred HRS | 2 | 18.0 |
Mice, Nude | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Histocytochemistry | 7 | 1.0 |
Transferrin/metabolism | 2 | 1.0 |
Cell Line | 16 | 0.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
Dichlororibofuranosylbenzimidazole/pharmacology | 2 | 7.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Chromatography, Gel | 5 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Milk, Human/immunology | 6 | 50.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Carrier Proteins/blood | 2 | 1.0 |
Corticotropin/blood | 2 | 1.0 |
Growth Hormone/*pharmacology | 4 | 5.0 |
Antibody Affinity | 2 | 1.0 |
Binding Sites, Antibody | 5 | 1.0 |
Dimerization | 2 | 0.0 |
Immunity, Mucosal | 2 | 2.0 |
Immunoglobulin A/metabolism | 5 | 9.0 |
Milk/immunology | 2 | 28.0 |
Risk Factors | 7 | 0.0 |
Survival Analysis | 3 | 0.0 |
Colostrum/immunology | 6 | 85.0 |
Biological Transport | 4 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Immunoelectrophoresis | 2 | 0.0 |
*Immunoglobulin A | 5 | 35.0 |
*Immunoglobulins, J-Chain | 3 | 100.0 |
Receptors, Polymeric Immunoglobulin/*metabolism | 4 | 50.0 |
Ultracentrifugation | 2 | 1.0 |
Electric Conductivity | 2 | 1.0 |
Cell Division | 6 | 0.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Interferon Type II/*pharmacology | 5 | 1.0 |
Recombinant Proteins | 4 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Delayed-Action Preparations | 2 | 1.0 |
*Models, Biological | 2 | 1.0 |
Immunoglobulin A/*metabolism | 10 | 34.0 |
Liver/*immunology | 3 | 7.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Water | 2 | 3.0 |
Anemia, Sickle Cell/*complications | 6 | 42.0 |
Bacterial Infections/*complications/microbiology/prevention & control | 2 | 100.0 |
Blotting, Northern | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Epithelium/immunology | 4 | 2.0 |
Intestinal Mucosa/*immunology | 3 | 3.0 |
Alkaline Phosphatase/blood | 3 | 2.0 |
Immunoblotting | 5 | 0.0 |
Child, Preschool | 27 | 0.0 |
Chronic Disease | 5 | 0.0 |
*Galvanic Skin Response/physiology | 2 | 100.0 |
*Heart Rate/physiology | 2 | 100.0 |
Psychiatric Status Rating Scales | 2 | 0.0 |
Severity of Illness Index | 5 | 0.0 |
Phenotype | 4 | 0.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Vaccinia virus/genetics | 2 | 2.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Epithelial Cells | 3 | 0.0 |
Cohort Studies | 5 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Estradiol/blood | 8 | 1.0 |
Follicle Stimulating Hormone/blood | 5 | 0.0 |
Leuprolide/*diagnostic use | 2 | 100.0 |
Luteinizing Hormone/blood | 5 | 0.0 |
Testosterone/blood | 3 | 0.0 |
Age Factors | 11 | 0.0 |
Genotype | 7 | 0.0 |
Reference Values | 8 | 0.0 |
Sex Factors | 12 | 0.0 |
Blood Cell Count | 3 | 1.0 |
Cell Separation | 2 | 0.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Combined Modality Therapy | 3 | 0.0 |
Secretory Component/*genetics | 2 | 40.0 |
Regression Analysis | 2 | 0.0 |
Rabbits | 12 | 0.0 |
Species Specificity | 6 | 0.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
C-Peptide/blood | 2 | 1.0 |
Insulin/blood | 4 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Macaca mulatta | 3 | 0.0 |
Progesterone/blood | 2 | 0.0 |
Recombinant Proteins/administration & dosage | 2 | 2.0 |
Neoplasm Transplantation | 2 | 0.0 |
Estrogens/pharmacology | 2 | 2.0 |
Insulin-Like Growth Factor I/*pharmacology | 3 | 2.0 |
Osteocalcin/blood | 2 | 2.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
Secretory Component/*biosynthesis/genetics | 2 | 66.0 |
*Immunoglobulin A, Secretory | 4 | 80.0 |
Phylogeny | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Protein Conformation | 5 | 0.0 |
*Software | 2 | 3.0 |
Free Radicals | 2 | 1.0 |
Down-Regulation | 2 | 0.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Pan troglodytes | 2 | 1.0 |
Body Weight/physiology | 2 | 2.0 |
Polyethylenes | 2 | 50.0 |
Serum Albumin/analysis | 2 | 1.0 |
Somatotropin-Releasing Hormone/administration & dosage/*pharmacology | 2 | 11.0 |
Rats, Inbred F344 | 2 | 0.0 |
Phosphopyruvate Hydratase/genetics | 3 | 23.0 |
Immunoglobulin A, Secretory/*urine | 2 | 100.0 |
Somatotropin-Releasing Hormone/*therapeutic use | 2 | 18.0 |
Cell Differentiation | 3 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Cross Reactions | 3 | 0.0 |
HIV-1/*immunology | 3 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
Acute Disease | 4 | 0.0 |
Gestational Age | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Drug Administration Schedule | 7 | 0.0 |
*Fertilization in Vitro | 2 | 1.0 |
Luteinizing Hormone/*blood | 5 | 4.0 |
Kidney Neoplasms/*therapy | 2 | 14.0 |
Neoplasm Metastasis | 2 | 0.0 |
Skin Physiology | 2 | 5.0 |
Recombinant Proteins/administration & dosage/therapeutic use | 3 | 7.0 |
Infusions, Parenteral | 2 | 1.0 |
Hemoglobin SC Disease/physiopathology | 2 | 100.0 |
Homozygote | 3 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Creatinine/metabolism | 2 | 2.0 |
Retrospective Studies | 5 | 0.0 |
Hemoglobin SC Disease/*complications | 4 | 100.0 |
Fluorescein Angiography | 3 | 2.0 |
Glucose Tolerance Test | 4 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Injections, Intravenous | 10 | 1.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
HIV Envelope Protein gp120/*immunology | 2 | 1.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
*Renal Dialysis | 2 | 0.0 |
Freezing | 2 | 2.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
HIV Envelope Protein gp120/genetics/*immunology | 2 | 10.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
Receptors, Immunologic | 3 | 8.0 |
Secretory Component/*genetics/isolation & purification/metabolism | 2 | 100.0 |
Octreotide/administration & dosage/*therapeutic use | 2 | 28.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Jejunum/immunology | 2 | 28.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Models, Structural | 2 | 1.0 |
Fetal Hemoglobin/analysis | 2 | 5.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
Immunoglobulins/*analysis | 2 | 2.0 |
Immunoglobulins, J-Chain/*analysis | 4 | 80.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Anemia, Sickle Cell/*blood | 5 | 16.0 |
Hemoglobin SC Disease/blood | 2 | 50.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Immunization | 2 | 0.0 |
Hemoglobin SC Disease/*blood | 2 | 100.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Catalysis | 2 | 0.0 |
Somatotropin-Releasing Hormone/*pharmacology | 3 | 3.0 |
Biological Availability | 2 | 0.0 |
Thyrotropin/blood | 2 | 0.0 |
Thyroxine/blood | 2 | 0.0 |
Triiodothyronine/blood | 2 | 0.0 |
Growth Hormone/*blood | 7 | 3.0 |
Immunoglobulin A, Secretory/*analysis | 8 | 61.0 |
Secretory Component/immunology | 3 | 100.0 |
Immunoglobulin M/*metabolism | 4 | 11.0 |
*Receptors, Fc | 2 | 28.0 |
Receptors, Immunologic/*metabolism | 4 | 2.0 |
Acromegaly/*drug therapy | 3 | 16.0 |
Administration, Intranasal | 2 | 2.0 |
Growth Hormone/blood | 3 | 1.0 |
*Hypophysectomy | 2 | 16.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Rats, Inbred Strains | 12 | 1.0 |
Feedback | 2 | 1.0 |
Immune Sera/immunology | 2 | 1.0 |
Immunization, Passive | 2 | 2.0 |
Somatostatin/immunology/*physiology | 2 | 50.0 |
Immune Sera | 2 | 0.0 |
Blood Glucose/metabolism | 3 | 0.0 |
Hemoglobin A, Glycosylated/analysis | 3 | 0.0 |
*Immunoglobulin A/analysis | 3 | 60.0 |
Epitopes | 5 | 0.0 |
Fetus/immunology | 2 | 5.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Erythrocytes/*pathology | 2 | 33.0 |
Haplotypes | 2 | 0.0 |
Octreotide/*pharmacology | 2 | 9.0 |
Acoustic Stimulation | 2 | 2.0 |
*Schizophrenic Psychology | 2 | 3.0 |
Antineoplastic Agents/administration & dosage/pharmacology | 2 | 100.0 |
Gonadorelin/administration & dosage/analogs & derivatives/pharmacology | 2 | 100.0 |
Injections | 2 | 1.0 |
Leuprolide | 2 | 20.0 |
Progesterone/metabolism | 2 | 2.0 |
Precipitin Tests | 2 | 0.0 |
Platelet Aggregation/drug effects | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Circadian Rhythm | 2 | 0.0 |
Secretory Component/analysis | 9 | 60.0 |
Globins/genetics | 2 | 1.0 |
Hemoglobin C Disease/blood/complications | 2 | 100.0 |
Antibody Specificity | 7 | 0.0 |
Immunoglobulin A/*immunology | 3 | 11.0 |
Immunoglobulin A, Secretory/immunology | 2 | 50.0 |
Secretory Component/*immunology | 4 | 100.0 |
*IgA Deficiency | 2 | 11.0 |
Immunoglobulin A, Secretory/analysis | 3 | 16.0 |
Immunoglobulin M/*analysis | 5 | 11.0 |
Biopsy | 4 | 0.0 |
Secretory Component/analysis/*metabolism | 2 | 100.0 |
CA-15-3 Antigen | 2 | 2.0 |
Buserelin/*pharmacology | 2 | 33.0 |
Immunoradiometric Assay | 2 | 1.0 |
Testis/drug effects | 2 | 25.0 |
Organ Size | 2 | 1.0 |
Immunoglobulin Fragments/*metabolism | 5 | 62.0 |
Blood Pressure | 2 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Hemoglobin SC Disease/blood/complications | 2 | 100.0 |
Jamaica | 5 | 22.0 |
Prevalence | 2 | 0.0 |
Milk, Human/*immunology | 2 | 13.0 |
Mucous Membrane/immunology | 3 | 11.0 |
Autoantibodies/*analysis | 7 | 3.0 |
Cytoskeleton/*immunology | 2 | 16.0 |
Clinical Trials | 4 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Netherlands | 2 | 1.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Immunoglobulin Fragments/*genetics | 2 | 40.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
*Synaptonemal Complex | 3 | 100.0 |
Culture Techniques | 2 | 0.0 |
Behavior, Animal/*drug effects | 4 | 18.0 |
Antibody-Producing Cells/*immunology | 2 | 12.0 |
T-Lymphocytes/classification/immunology | 2 | 11.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Colonic Neoplasms/*immunology | 2 | 8.0 |
*Immunoglobulin Fragments/analysis | 2 | 100.0 |
Blood Glucose/*analysis | 2 | 1.0 |
Xylose/blood | 2 | 100.0 |
Immunoglobulin Fragments/*analysis | 13 | 86.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Glucagon/blood | 3 | 3.0 |
Octreotide | 4 | 33.0 |
Immunoglobulin M/metabolism | 2 | 2.0 |
Epitopes/*analysis | 2 | 1.0 |
Intestinal Mucosa/immunology | 3 | 5.0 |
Colostrum/*immunology | 2 | 25.0 |
Acromegaly/blood/*drug therapy | 3 | 21.0 |
Testosterone/*blood | 2 | 0.0 |
Immunoglobulin A/*analysis | 7 | 12.0 |
Epidermis/immunology | 2 | 9.0 |
Keratin/*immunology | 3 | 30.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Antibodies/*analysis | 2 | 1.0 |
Skin/immunology | 3 | 3.0 |
Immunoglobulin Fragments/*immunology | 4 | 28.0 |
Immunoglobulins, Fab | 2 | 3.0 |
Spermatogenesis/*drug effects | 2 | 25.0 |
Asialoglycoprotein Receptor | 2 | 8.0 |
Hemoglobin C/analysis | 2 | 50.0 |
Immunodiffusion/methods | 2 | 11.0 |
Erythrocyte Indices | 2 | 3.0 |
*Menstruation | 2 | 5.0 |
Secretory Component/metabolism | 2 | 22.0 |
*Immunoglobulin Fragments | 7 | 70.0 |
Immunoglobulin M/*immunology | 2 | 3.0 |
Immunoglobulins, Fc/immunology | 2 | 8.0 |
*Secretory Component | 7 | 100.0 |
Immunoglobulin A/biosynthesis | 2 | 7.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Immunoglobulin M/biosynthesis | 3 | 3.0 |
Cytoplasm/immunology | 2 | 2.0 |
*Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, 1-3 | 7 | 12.0 |
*Linkage (Genetics) | 4 | 0.0 |
Recombination, Genetic | 7 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Absorption | 2 | 1.0 |
Epidermis/*immunology | 2 | 16.0 |
Antigens | 2 | 2.0 |
Gastric Mucosa/immunology/pathology | 2 | 22.0 |
Gastritis/pathology | 2 | 33.0 |
Gastrointestinal Diseases/*immunology/pathology | 2 | 100.0 |
Immunoglobulins/analysis/classification | 2 | 66.0 |
Metaplasia/immunology | 2 | 66.0 |
T-Lymphocytes/classification | 2 | 6.0 |
Atropine/pharmacology | 2 | 5.0 |
Atropine Derivatives/pharmacology | 2 | 100.0 |
Haloperidol/pharmacology | 2 | 9.0 |
Parasympathetic Nervous System/*physiology | 2 | 14.0 |
Physostigmine/pharmacology | 2 | 12.0 |
Protirelin/*pharmacology | 3 | 4.0 |
Receptors, Dopamine/*physiology | 2 | 18.0 |
Salivation/drug effects | 2 | 50.0 |
Stereotyped Behavior/drug effects | 2 | 13.0 |
Tremor/chemically induced | 2 | 33.0 |
Liver Cirrhosis/immunology | 2 | 14.0 |
Immunoglobulin A/*biosynthesis | 2 | 25.0 |
Immunoglobulins, J-Chain/analysis | 3 | 50.0 |
Antibodies/analysis | 2 | 1.0 |
Skin/*immunology | 2 | 1.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Saliva/immunology | 4 | 14.0 |
Complement 3/analysis | 2 | 0.0 |
Aging | 2 | 0.0 |
Infertility, Male/*genetics | 2 | 4.0 |
Linkage (Genetics) | 3 | 0.0 |
Immunoglobulin Fragments/*biosynthesis | 2 | 100.0 |
*Immunoglobulin A, Secretory/analysis | 2 | 100.0 |
Immunoglobulin E/analysis | 2 | 3.0 |
Antibody Formation | 2 | 0.0 |
Psoriasis/*immunology | 2 | 11.0 |
Secretory Component | 2 | 66.0 |
Phosphoglucomutase/genetics | 2 | 4.0 |
Phosphogluconate Dehydrogenase/genetics | 2 | 7.0 |
Rh-Hr Blood-Group System | 3 | 8.0 |
Uridine Kinase/genetics | 2 | 100.0 |
*Blood Group Antigens | 2 | 3.0 |
Duffy Blood-Group System | 2 | 33.0 |
*Genes, Structural | 2 | 0.0 |
Multiple Myeloma/immunology | 2 | 11.0 |
